Berlin (dpa) - The pharmaceutical company Bayer is considering getting into the production of corona vaccines.
"We are discussing with Curevac and also with politicians and the authorities what can be done," says Bayer boss Werner Baumann of "Welt am Sonntag".
“With our production network in Germany and the USA and the appropriate lead time, we would be able to produce vaccines in larger quantities.
We are currently testing this under high pressure. "
This is not primarily about financial considerations, but about making the vaccine available as soon as possible.
At the beginning of the month Bayer and the Tübingen biotech company Curevac signed a cooperation and service agreement.
Curevac has been developing the corona vaccine CVnCoV for a long time, for which the approval-relevant clinical phase III study began in mid-December.
Curevac expects the first results towards the end of March.
In the event of approval, the EU Commission has secured 405 million doses for the EU states.
Bayer should now take part in the necessary study during approval work and also keep an eye on the supply chains.
The contract does not include the fact that the group will also take over production.
In addition, Curevac remains the holder of a marketing authorization.
Bayer would, however, have the option of becoming a holder of the approval in certain markets outside of Europe.
© dpa-infocom, dpa: 210117-99-57465 / 2